MELBOURNE, Australia--(BUSINESS WIRE)--Biotechnology company Avexa Limited (ASX:AVX) announced today that it has initiated the Phase III program for apricitabine (ATC), its anti-HIV drug. The Company recently received positive feedback from regulatory agencies allowing ATC’s progress into pivotal, filing studies.
